What changed from existing technology?
This study tested a new drug called SHR-A1811 for breast cancer that is hormone receptor positive and has low levels of HER2. The drug was given before surgery to see if it could shrink the tumor.
This is the first study to evaluate SHR-A1811 as a neoadjuvant therapy for HR+/HER2-low breast cancer, showing promising results in tumor response and safety.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
n Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015). As an anti-HER2 antibody-drug conjugate, SHR-A1811 has exhibited s
Title ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This study suggests SHR-A1811 may be a potential treatment option for HR+/HER2-low breast cancer, but further research is needed to confirm its long-term benefits and optimal use.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.